The Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
Department of Molecular Genetics, University of Toronto, Ontario, Canada.
Nat Biotechnol. 2018 Jan;36(1):95-102. doi: 10.1038/nbt.4021. Epub 2017 Nov 27.
Programmable nucleases, such as Cas9, are used for precise genome editing by homology-dependent repair (HDR). However, HDR efficiency is constrained by competition from other double-strand break (DSB) repair pathways, including non-homologous end-joining (NHEJ). We report the discovery of a genetically encoded inhibitor of 53BP1 that increases the efficiency of HDR-dependent genome editing in human and mouse cells. 53BP1 is a key regulator of DSB repair pathway choice in eukaryotic cells and functions to favor NHEJ over HDR by suppressing end resection, which is the rate-limiting step in the initiation of HDR. We screened an existing combinatorial library of engineered ubiquitin variants for inhibitors of 53BP1. Expression of one variant, named i53 (inhibitor of 53BP1), in human and mouse cells, blocked accumulation of 53BP1 at sites of DNA damage and improved gene targeting and chromosomal gene conversion with either double-stranded DNA or single-stranded oligonucleotide donors by up to 5.6-fold. Inhibition of 53BP1 is a robust method to increase efficiency of HDR-based precise genome editing.
可编程核酸酶,如 Cas9,可用于通过同源依赖性修复(HDR)进行精确的基因组编辑。然而,HDR 效率受到其他双链断裂(DSB)修复途径的竞争限制,包括非同源末端连接(NHEJ)。我们报告了一种 53BP1 的基因编码抑制剂的发现,该抑制剂可提高人类和小鼠细胞中 HDR 依赖性基因组编辑的效率。53BP1 是真核细胞 DSB 修复途径选择的关键调节剂,通过抑制末端切除来有利于 NHEJ 而不是 HDR,末端切除是 HDR 起始的限速步骤。我们筛选了一个现有的工程化泛素变体组合文库,以寻找 53BP1 的抑制剂。在人类和小鼠细胞中表达一种名为 i53(53BP1 抑制剂)的变体,可阻止 53BP1 在 DNA 损伤部位的积累,并将双链 DNA 或单链寡核苷酸供体的基因靶向和染色体基因转换效率提高高达 5.6 倍。53BP1 的抑制是提高基于 HDR 的精确基因组编辑效率的一种有效方法。